ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

ClinicalTrials.gov ID: NCT06534892

Public ClinicalTrials.gov record NCT06534892. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b, Randomized, Open Label, Multicountry, Multi-center, Extension and Crossover Vaccination Study to Evaluate the Immunogenicity and Safety of Different Revaccination Schedules and Persistence of a Single Dose of the RSVPreF3 OA Vaccine in Adults Aged 60 Years and Above Who Participated in the RSV OA=ADJ-006 Study

Study identification

NCT ID
NCT06534892
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
10,212 participants

Conditions and interventions

Interventions

  • RSVPreF3 OA vaccine Biological

Biological

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2024
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update posted
Apr 19, 2026

2024 – 2026

United States locations

U.S. sites
55
U.S. states
23
U.S. cities
53
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35205
GSK Investigational Site Birmingham Alabama 35211
GSK Investigational Site Huntsville Alabama 35802
GSK Investigational Site Phoenix Arizona 85020
GSK Investigational Site Tucson Arizona 85741
GSK Investigational Site Cerritos California 90703
GSK Investigational Site Doral Florida 33172
GSK Investigational Site Fort Myers Florida 33912
GSK Investigational Site Jacksonville Florida 32205
GSK Investigational Site Lake City Florida 32055
GSK Investigational Site Melbourne Florida 32934
GSK Investigational Site Miami Florida 33174
GSK Investigational Site Orlando Florida 32806
GSK Investigational Site Pinellas Park Florida 33781
GSK Investigational Site The Villages Florida 32162
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Atlanta Georgia 30328
GSK Investigational Site Savannah Georgia 31406
GSK Investigational Site Chicago Illinois 60602
GSK Investigational Site Evansville Indiana 47714
GSK Investigational Site Mishawaka Indiana 46544
GSK Investigational Site El Dorado Kansas 67042
GSK Investigational Site Newton Kansas 67114
GSK Investigational Site Wichita Kansas 67205
GSK Investigational Site Wichita Kansas 67226
GSK Investigational Site Lexington Kentucky 40509
GSK Investigational Site Rockville Maryland 20854
GSK Investigational Site Richfield Minnesota 55423
GSK Investigational Site Kansas City Missouri 64114
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Omaha Nebraska 68134
GSK Investigational Site Las Vegas Nevada 89113
GSK Investigational Site New York New York 10017
GSK Investigational Site Rochester New York 14609
GSK Investigational Site Hickory North Carolina 28601
GSK Investigational Site Mooresville North Carolina 28117
GSK Investigational Site Rocky Mount North Carolina 27804
GSK Investigational Site Salisbury North Carolina 28144
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Centerville Ohio 45459
GSK Investigational Site Cincinnati Ohio 45236
GSK Investigational Site Columbus Ohio 43212
GSK Investigational Site Erie Pennsylvania 16508
GSK Investigational Site Pittsburgh Pennsylvania 15236
GSK Investigational Site Anderson South Carolina 29621
GSK Investigational Site Mt. Pleasant South Carolina 29405
GSK Investigational Site Knoxville Tennessee 37938
GSK Investigational Site Memphis Tennessee 38119
GSK Investigational Site Dallas Texas 75234
GSK Investigational Site Fort Worth Texas 76104
GSK Investigational Site Houston Texas 77008
GSK Investigational Site Keller Texas 76248
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Salt Lake City Utah 84106
GSK Investigational Site Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 194 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06534892, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 19, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06534892 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →